Ligand Pharmaceuticals | LGND - Interest Expense On Debt


Ligand Pharmaceuticals reported $910K in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Amgen USD 653M 32M Dec/2025
Arrowhead Research USD 21.69M 2.69M Sep/2025
Baxter International USD 58M 14M Sep/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline GBP 167M 17M Sep/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Insmed USD 20.38M 863K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Pacira USD 4.28M 456K Sep/2025
Pfizer USD 711M 59M Dec/2025
Veracyte USD 2K 1000 Dec/2023